Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
Onishi A, Matsumura-Kimoto Y, Mizutani S, Isa R, Fujino T, Tsukamoto T, Miyashita A, Okumura K, Nishiyama D, Hirakawa K, Shimura K, Kaneko H, Kiyota M, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Onishi A, et al. Among authors: hirakawa k. Int J Hematol. 2024 Jan;119(1):50-61. doi: 10.1007/s12185-023-03680-1. Epub 2023 Dec 12. Int J Hematol. 2024. PMID: 38082201
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: hirakawa k. Cancer Rep (Hoboken). 2022 Feb;5(2):e1476. doi: 10.1002/cnr2.1476. Epub 2021 Jun 14. Cancer Rep (Hoboken). 2022. PMID: 34124862 Free PMC article.
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: hirakawa k. Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24. Int J Hematol. 2022. PMID: 35072907
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.
Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Muramatsu A, et al. Among authors: hirakawa k. Leuk Lymphoma. 2022 Jul;63(7):1678-1685. doi: 10.1080/10428194.2022.2038373. Epub 2022 Feb 11. Leuk Lymphoma. 2022. PMID: 35147475
Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective study.
Mizuhara K, Kobayashi T, Nakao M, Takahashi R, Kaneko H, Shimura K, Hirakawa K, Uoshima N, Wada K, Kawata E, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Yoneda A, Watanabe A, Sotozono C, Kuroda J. Mizuhara K, et al. Among authors: hirakawa k. Cancer Med. 2023 Feb;12(3):3134-3144. doi: 10.1002/cam4.5237. Epub 2022 Sep 12. Cancer Med. 2023. PMID: 36097396 Free PMC article.
Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
Okamoto H, Inoue Y, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida SI, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J; KOTOSG investigators. Okamoto H, et al. Among authors: hirakawa k. Int J Hematol. 2023 Sep;118(3):323-332. doi: 10.1007/s12185-023-03627-6. Epub 2023 Jun 28. Int J Hematol. 2023. PMID: 37378717
Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.
Inoue Y, Okamoto H, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida SI, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J. Inoue Y, et al. Among authors: hirakawa k. Oncol Lett. 2023 Dec 18;27(2):62. doi: 10.3892/ol.2023.14193. eCollection 2024 Feb. Oncol Lett. 2023. PMID: 38192677 Free PMC article.
1,462 results